Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi (NASDAQ: SNY) Q3 2024 Earnings Call Oct 25, 2024, 8:00 a.m. ET Welcome to the Q3 2024 conference call for investors ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

Sanofi attributed its double-digit growth to growth in vaccines, particularly its latest flu jab. Another major revenue ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the ...

The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...

French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...